Cardiovascular Systems

Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cardiovascular Systems, Inc. (CSI) is devoted to developing and commercializing innovative solutions for treating peripheral and coronary vascular disease. Their primary focus is helping physicians conquer even the most difficult disease states, including calcium, given the complications. Cardiovascular Systems develop solutions for the treatment of peripheral and coronary artery disease, to help physicians conquer calcium, one of the largest challenges when treating PAD and CAD.

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2022 SECOND QUARTER FINANCIAL RESULTS

Cardiovascular Systems, Inc. Reports Fiscal 2022 Second Quarter Financial Results

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO PARTICIPATE AT SVB LEERINK 2022 GLOBAL HEALTHCARE CONFERENCE

Cardiovascular Systems, Inc. to Participate at SVB Leerink 2022 Global Healthcare Conference

Cardiovascular Systems Inc (NASDAQ: CSII), along with OrbusNeich Medical Company Ltd, have received FDA PMA approval for OrbusNeich's Scoreflex NC Scoring Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheter (Scoreflex NC). Scoreflex NC is a focused force PTCA scoring balloon with a dual-wire system that creates a focal stress pattern to facilitate safe and controlled plaque modification at lower resolution pressure.

Cardiovascular Systems, OrbusNeich Scores FDA Approval For Scoreflex Scoring Balloon

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. AND ORBUSNEICH ANNOUNCE FDA PMA APPROVAL OF SCOREFLEX® SCORING BALLOON

Cardiovascular Systems, Inc. and OrbusNeich Announce FDA PMA Approval of Scoreflex® Scoring Balloon

Cardiovascular Systems (CSII) has developed intravascular lithotripsy systems to treat calcific coronary and peripheral artery diseases.

Cardiovascular Systems (CSII) Expands Lithotripsy Technology

Cardiovascular Systems Inc (NASDAQ: CSII) has announced the development of intravascular lithotripsy (IVL) technology for coronary and peripheral artery diseases. Enrolling patients in an investigational device exemption study for the CSI coronary IVL system is currently targeted for calendar 2023.

Cardiovascular Systems To Develop IVL Technology For Coronary, Peripheral Artery Diseases

ST. PAUL, Minn.--(BUSINESS WIRE)--CSI ANNOUNCES DEVELOPMENT OF INTRAVASCULAR LITHOTRIPSY TECHNOLOGY FOR THE TREATMENT OF CORONARY AND PERIPHERAL ARTERY DISEASES

Cardiovascular Systems, Inc. Announces Development of Intravascular Lithotripsy Technology for the Treatment of Coronary and Peripheral Artery Diseases

Cardiovascular Systems (CSII) continues to experience strong demand for physician training and certification in all international markets.

Cardiovascular Systems (CSII) Coronary Sales Up Amid COVID Woe

Cardiovascular Systems Inc (NASDAQ: CSII) is recalling all of its Wirion embolic protection system devices manufactured and distributed between January and November 2021. The Wirion system includes a filter inserted through a blood vessel in the leg via a catheter.

Cardiovascular Systems Recalls Embolic Protection Devices Due To Filter Breakage

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. to Webcast Fiscal 2022 Second-Quarter Earnings Conference Call Thursday, February 3

CORRECTING and REPLACING Cardiovascular Systems, Inc. to Webcast Fiscal 2022 Second-Quarter Earnings Conference Call Thursday, February 3

Cardiovascular Systems, Inc. to Webcast Fiscal 2022 Second-Quarter Earnings Conference Call Thursday, February 3

Autohome

Bloomin' Brands

Kelly Services

Lumber Liquidators

CSII, KELYA, LL, ATHM, and BLMN have been added to the Zacks Rank #5 (Strong Sell) List on December 3, 2021

New Strong Sell Stocks for December 3rd

Cardiovascular Systems Inc (NASDAQ: CSII) has commenced a voluntary recall of its WIRION Embolic Protection Systems (WIRION). The unused WRN-D6 models of the WIRION device are being recalled due to receiving complaints regarding filter breakage at the time of retrieval.

Cardiovascular Systems Recalls Wirion Embolic Protection System

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. Initiates Voluntary Recall of WIRION® Embolic Protection System

Cardiovascular Systems, Inc. Initiates Voluntary Recall of WIRION® Embolic Protection System

According to Cardiovascular Systems (CSII), the resurgence of COVID-19 and the related staffing shortages are disrupting referral patterns and having the largest impact on elective procedures.

Cardiovascular Systems (CSII) Business Down on COVID Resurgence

Cardiovascular Systems' (CSII) coronary franchise registers strong performance globally on continued strength in Japan and Europe.

Cardiovascular Systems (CSII) Q1 Loss Wider Than Expected

Cardiovascular Systems, Inc. (CSII) CEO Scott Ward on Q1 2022 Results - Earnings Call Transcript

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -120.00% and -7.80%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Cardiovascular Systems (CSII) Reports Q1 Loss, Lags Revenue Estimates

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2022 FIRST QUARTER FINANCIAL RESULTS

Cardiovascular Systems, Inc. Reports Fiscal 2022 First Quarter Financial Results

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. Announces First In-Human Experience With Coronary Everolimus Drug Coated Balloon

Cardiovascular Systems, Inc. Announces First In-Human Experience With Coronary Everolimus Drug Coated Balloon

Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Cardiovascular Systems (CSII) to Report a Decline in Earnings: What to Look Out for

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. to Participate at the Stifel 2021 Virtual Healthcare Conference

Cardiovascular Systems, Inc. to Participate at the Stifel 2021 Virtual Healthcare Conference

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO WEBCAST FISCAL 2022 FIRST-QUARTER EARNINGS CONFERENCE CALL TUESDAY, NOVEMBER 9

Cardiovascular Systems, Inc. to Webcast Fiscal 2022 First-Quarter Earnings Conference Call Tuesday, November 9

Cardiovascular Systems' (CSII) ViperCross offers the correct balance of support and flexibility to navigate tortuous anatomy and cross challenging lesions.

Cardiovascular Systems (CSII) Treats 1st Patient With ViperCross

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES FIRST PATIENT TREATED WITH VIPERCROSS™ PERIPHERAL SUPPORT CATHETER

News for Cardiovascular Systems Stock (CSII)